Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5164-5170

  Han, Jennifer H ^a   Mascitti, Kara B ^b   Edelstein, Paul H ^a   Bilker, Warren B ^a   Lautenbach, Ebbing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ST LUKE S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BLOOD CULTURE; COST OF ILLNESS; FEMALE; HOSPITAL CHARGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STAPHYLOCOCCAL BACTEREMIA;

ADULT; AGED; BACTEREMIA; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84866327609     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00757-12     Document Type: Article

References (44)

1. AB Biodisk. 2008. Etest technical manual. AB Biodisk, Solna, Sweden.
2. Aguado JM, et al. 2011. High vancomycin MIC and complicated methi-cillin- susceptible Staphylococcus aureus bacteremia. Emerg. Infect. Dis. 17:1099-1102.
3. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Cosgrove SE, et al. 2003. Comparison of mortality associated with me-thicillin- resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36:53-59. (Pubitemid 36099097)
7. Cosgrove SE, et al. 2005. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 26:166-174. (Pubitemid 40445022)
8. Ender M, McCallum N, Adhikari R, Berger-Bachi B. 2004. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob. Agents Chemother. 48:2295-2297. (Pubitemid 38691635)
9. Fitzgibbon MM, Rossney AS, O'Connell B. 2007. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. J. Clin. Microbiol. 45:3263-3269. (Pubitemid 47585649)
10. Fowler VG, et al. 2004. Persistent bacteremia due to methicillin- resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J. Infect. Dis. 190:1140-1149.
11. Gasink LB, et al. 2006. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am. J. Med. 119:526.e19-526.e25.
12. Grogger JT, Carson RT. 1991. Models for truncated counts. J. Appl. Econom. 6:225-238.
13. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. 2011. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int. J. Antimicrob. Agents 37:219-224.
14. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144. (Pubitemid 44631403)
15. Hidron AI, et al. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
16. Holland TL, Fowler VG. 2011. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? J. Infect. Dis. 204:329-331.
17. Holmes NE, et al. 2011. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204:340-347.
18. Hsu DI, et al. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32:378-385.
19. Iezzoni LI, et al. 1995. Predicting who dies depends on how severity is measured: implications for evaluating patient outcomes. Ann. Intern. Med. 123:763-770.
20. Klevens RM, et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. (Pubitemid 47598444)
21. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981.
22. Lalueza A, et al. 2010. Is high vancomycin minimum inhibitory concen- tration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J. Infect. Dis. 201:311-312.
23. Lee I, et al. 2009. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch. Intern. Med. 169:379-383.
24. Lina G, et al. 1999. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29:1128-1132. (Pubitemid 30265628)
25. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55.
26. Lodise TP, et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
27. Mickey RM, Greenland S. 1989. The impact of confounder selection criteria on effect estimation. Am. J. Epidemiol. 129:125-137. (Pubitemid 19030705)
28. Moise PA, Sakoulas G, Forrest A, Schentag JJ. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586. (Pubitemid 47047340)
29. Moise-Broder PA, et al. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700-1705. (Pubitemid 38781661)
30. Peleg AY, et al. 2009. Reduced susceptibility to vancomycin influence pathogenicity in Staphylococcus aureus infection. J. Infect. Dis. 199:532-536.
31. Price J, Atkinson S, Llewelyn M, Paul J. 2009. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin. Infect. Dis. 48:997-998.
32. Quan H, et al. 2005. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care 43:1130-1139. (Pubitemid 41587600)
33. Sakoulas G, et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402. (Pubitemid 38747480)
34. Satola SW, Farley MM, Anderson KF, Patel JB. 2011. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J. Clin. Microbiol. 49:177-183.
35. Schweizer ML, et al. 2011. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob. Agents Chemother. 55:1082-1087.
36. Soriano A, et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200. (Pubitemid 351269157)
37. Steinkraus G, White R, Friedrich L. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin- susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794. (Pubitemid 47434257)
38. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54:755-771.
39. Vaudaux P, et al. 2010. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 54:3861-3870.
40. Wang G, Hindler JF, Ward KW, Bruckner DA. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886. (Pubitemid 44737223)
41. Wang JL, et al. 2008. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clin. Infect. Dis. 46:799-806.
42. Wang J-L, Wang J-T, Sheng W-H, Chen Y-C, Chang S-C. 2010. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/liter, by the broth microdilution method. BMC Infect. Dis. 10:159.
43. Wootton M, MacGowan AP, Walsh TR, Howe RA. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329-332.
44. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. 2010. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteremia in patients treated with vancomycin. J. Antimicrob. Chemother. 65:1015-1018.